Sectors
CADL
Candel Therapeutics, Inc.
10.85
2 x 7.49
2 x 13.51
bid
ask
-
0.49
4.32%
2 @ 07:30 PM
10.75 -0.10 (0.92%)
| Ytd | 92.04% | |
| 1y | 119.64% |
10.78
day range
11.38
4.42
52 week range
13.75
| Open | 11.28 | Prev Close | 11.34 | Low | 10.78 | High | 11.38 | Mkt Cap | 830.23M |
| Vol | 3.01M | Avg Vol | 1.38M | EPS | -1.47 | P/E | N/A | Forward P/E | -21.12 |
| Beta | -0.50 | Short Ratio | 10.24 | Inst. Own | 66.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.19 | 200-d Avg | 7.66 | 1yr Est | 21.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.3 | N/A | N/A | N/A |
| 2026-08-13 | 2026-06 | -0.24 | -0.52 | -0.28 | -118.55% |
| 2026-05-14 | 2026-03 | -0.22 | -0.14 | 0.08 | 36.36% |
| 2026-03-12 | 2025-12 | -0.24 | -0.54 | -0.3 | -125.00% |
| 2025-11-13 | 2025-09 | -0.17 | -0.21 | -0.04 | -23.53% |
| 2025-08-14 | 2025-06 | -0.17 | -0.09 | 0.08 | 47.06% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-14 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-13 | Stifel | Upgrade | Buy | |
| 2026-04-20 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-03-18 | Citigroup | Upgrade | Buy | Buy |
| 2026-03-13 | Citigroup | Upgrade | Buy | Buy |
Profile
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-14 | AGUILAR-CORDOVA ESTUARDO | Beneficial Owner of more than 10% of a Class of Security | 6.05M | Sale |
| 2026-06-28 | BARONE FRANCESCA | Officer | 77.36K | Sale |
| 2026-02-22 | MANNING PAUL B. | Director | 0.00 | Purchase |
| 2025-06-24 | MARTELL CHRISTOPHER | Director | 0.00 | Stock Award(Grant) |
| 2025-06-24 | NABEL GARY J. | Director | 5.35K | Stock Award(Grant) |
| 2025-07-27 | NICHOLS WILLIAMS GARRETT | Officer | 52.49K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 10.99M | 145.08M | 14.36% |
| 2026-06-29 | RTW Investments LP | 6.42M | 84.77M | 8.39% |
| 2026-06-29 | Blackrock Inc. | 4.97M | 65.59M | 6.49% |
| 2026-06-29 | State Street Corporation | 3.55M | 46.86M | 4.64% |
| 2026-06-29 | Acorn Capital Advisors, LLC | 3.50M | 46.17M | 4.57% |
| 2026-06-29 | Portolan Capital Management, LLC | 3.49M | 46.07M | 4.56% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 4.86M | 64.21M | 6.36% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.11M | 27.83M | 2.76% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.02M | 26.72M | 2.65% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.97M | 25.98M | 2.57% |
| 2026-06-29 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 1.91M | 25.23M | 2.50% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.65M | 21.79M | 2.16% |